PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Ltd. has recruited the first patient in its revised SHIELD II Phase 3 trial for D-PLEX100, a late-stage biopharma product aimed at preventing abdominal colorectal surgical site infections. The US Food and Drug Administration recently accepted the company’s revised protocol for the study, which will enroll an estimated 550 patients undergoing colorectal resection surgery with large incisi..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 23.
  • textsms

China Approves the World's First Vaccine against XBB Descendent Lineages of SARS-CoV-2 for Emergency Use

China has approved the world's first vaccine against XBB descendent lineages of SARS-CoV-2 for emergency use. The Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine, developed by WestVac Biopharma/West China Medical Center, Sichuan University, is a broad-spectrum COVID-19 vaccine against multiple prevalent subvariants locally and internationally, inc..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 10.
  • textsms

Shionogi Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection

Japanese pharmaceutical company Shionogi has enrolled the first participant in its global Phase 3 trial of Ensitrelvir, an oral antiviral designed to prevent symptomatic SARS-CoV-2 infection. The study will evaluate the drug's safety and efficacy in preventing infection among people exposed to household contacts who have tested positive for COVID-19. Approximately 2,200 participants across North..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 10.
  • textsms